To include your compound in the COVID-19 Resource Center, submit it here.

Cytokinetics starts Phase II trial of CK-2127107 to treat ALS

Cytokinetics Inc. (NASDAQ:CYTK) began the Phase II FORTITUDE-ALS trial of CK-2127107 (CK-107) to treat amyotrophic lateral sclerosis (ALS). The double-blind,

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE